$ALECBearishLow

Wong-Sarad Grace sold $11K of ALEC

Wong-Sarad Grace (Principal Accounting Officer) sold 5,709 shares of Alector, Inc. (ALEC) at $1.97 on 2026-06-02.

6/10
6/10
Low
Bearish
after-hours/filing update (SEC Form 4 filed today)
slightly negative (insider selling without 10b5-1)

Insider selling is a negative signal, but this is a small, non-10b5-1 sale and typically has limited standalone impact.

Alector insider (principal accounting officer) sold 5,709 shares in an open-market transaction disclosed on SEC Form 4.

Likely minimal near-term price impact; may slightly pressure sentiment if traders view it as lack of conviction.

Background

This is an SEC Form 4 insider transaction: Wong-Sarad Grace (principal accounting officer) sold shares on 2026-06-02, filed 2026-06-03.

Why it matters

Traders may reassess short-term sentiment, but the disclosure alone is unlikely to change fundamental expectations absent corroborating news (guidance, trial, financing, or partnership).

Market relevance

A single insider sale (non-10b5-1) can nudge sentiment, but the disclosed value (~$11.27K) suggests limited fundamental impact.

Market effects

No clear sector read-through from a single, small insider sale.

None indicated.

None indicated.

Alternative perspectives

The sale may be driven by personal liquidity needs or diversification rather than a bearish view, especially given the small dollar amount.

The absence of a 10b5-1 plan increases interpretive uncertainty; without context on prior holdings/sale frequency, signal strength is limited.

Key entities

  • Alector, Inc.

    Subject of the insider sale disclosure on SEC Form 4 (ALEC).

  • Wong-Sarad Grace

    Principal Accounting Officer who sold 5,709 shares open-market.

Related articles

$ALECMedAI 8/10

UAE Business: ALEC unit Target wins $500m three EPC contracts in Gulf

ALEC Holdings said its subsidiary Target Engineering Construction Company – SP won three Gulf EPC contracts totaling over $500 million, according to a filing to the Dubai Stock Market. The projects have execution periods of 10, 21 and 36 months. ALEC said the awards’ financial impact will be recognized over those periods under its revenue policy, and it did not name clients, locations or scope.

$ALECLow

Alector (NASDAQ: ALEC) Q1 2026 results, trial halt and ABC focus

Alector (NASDAQ: ALEC) reported its Q1 2026 financial results, revealing a narrowed net loss of $22.9 million and a strategic pivot towards its Alector Brain Carrier (ABC) platform. This shift follows the discontinuation of its Phase 2 Alzheimer's trial for nivisnebart due to a futility analysis. The company maintains a cash runway expected to fund operations through at least 2027, focusing on advancing multiple preclinical ABC-enabled programs for neurodegenerative diseases.

$ALECMed

Alector (ALEC) CEO awarded 116,246 RSUs, boosts direct share stake

Alector, Inc. CEO Arnon Rosenthal was granted 116,246 restricted stock units (RSUs) on March 13, 2026, as equity compensation. These RSUs, which have no cash cost, will vest in two equal installments on September 1, 2026, and March 1, 2027. This grant increases his direct ownership to 2,454,422 common shares, in addition to indirect holdings through family trusts.

$ALECMed

Alector (ALEC) Appoints Neil Berkley as CFO

Alector (ALEC) has appointed Neil Berkley as Chief Financial Officer, effective December 10, 2025, while he will also retain his responsibilities as Chief Business Officer. The biotechnology company, which focuses on neurodegenerative therapies, faces significant financial challenges including negative margins and declining revenue growth. Despite a stable liquidity position, an Altman Z-Score of -3.61 indicates potential bankruptcy risk, and recent insider activity shows substantial selling with no buying.